A 77-year-old man was diagnosed with secondary to late onset Alzheimer’s disease. Fourteen months post the diagnosis, patient began treatment with 10 mg memantine. After thirteen months of treatment, patient’s scores on MMSE and FAST were 10 and 5 respectively. Further, significant deterioration of cognitive function was observed after 3 months. His current MMSE and FAST scores were 3 and 7 respectively.
Results
#1. Which of the following will be best to improve cognitive function?
Use of deoxyribonuclease I in adjunct with memantine demonstrated noticeable recovery in cognitive and motor function so much so that after two months of therapy the MMSE and FAST scores were 18 and 4 respectively. It pinpoints towards the presence of a deoxyribonuclease-sensitive target that was involved in generating alzheimer’s symptoms. Cell free DNA appears to have a crucial role in the progression of a number of diseases but the evaluation of its role in AD is yet to be found.
